SENS

Sensyne Health and Sentara Healthcare Form New Partnership for Ethical Data Sharing and Design of New Clinical Algorithms

Retrieved on: 
Thursday, August 19, 2021
Research, Technology, Security, Cardiology, Software, Biotechnology, General Health, Health, Data Management, Science, HIPAA, Legislation, SENS, LSE, Data, Research, Foundation for Strategic Research, Disease, SRA, Health, Outline of health sciences, Forbes, Health Insurance Portability and Accountability Act, AI, Hospital, Consistency, CKD, Safety, CHF, Patient, Partnership, Algorithm, IBM, Health equity, Accountability Act, Watson (computer), Pharmaceutical industry, Medical device, Management, Medicine, Medical imaging, Sensyne Health, Sentara:, SENSYNE HEALTH, SENTARA:

Sentara will join 11 UK NHS Trusts and U.S. Health Systems who are partners and shareholders in Sensyne Health.

Key Points: 
  • Sentara will join 11 UK NHS Trusts and U.S. Health Systems who are partners and shareholders in Sensyne Health.
  • The partnership combines both life sciences research and healthcare algorithm development that will deliver value back to Sentara and its patients.
  • The agreement will enable the ethical application of clinical AI research by Sensyne through analyzing Sentaras patient dataset to improve patient care and accelerate medical research.
  • The Sensyne partnership has the potential to help our organization continue our mission of improving health every day in critical areas of healthcare, including health equity."

Sasol delivered a strong set of results for the year ended 30 June 2021

Retrieved on: 
Monday, August 16, 2021
CFO, EBITDA, Audit committee, SENS, RCF, Company, IAS, SA, Q&A, Retirement, Webcast, Board, Investment, Risk management, New, JSE, Safety, Capital market, PricewaterhouseCoopers, Bank, Animal, Audit, Management, Renewable energy

This will create valuable financial flexibility as we execute our Future Sasol strategy in the midst of an uncertain macroeconomic environment.

Key Points: 
  • This will create valuable financial flexibility as we execute our Future Sasol strategy in the midst of an uncertain macroeconomic environment.
  • Our objective remains to steer the balance sheet metrics toward restoration of our investment grade levels.
  • At 30 June 2021, our total debt was R102,9 billion compared to R189,7 billion at 30 June 2020.
  • Our gearing decreased from 117,0% at 30 June 2020 to 61,5% at 30 June 2021 mainly due to repayment of US dollar debt and a stronger closing rand/US dollar exchange rate.

Sasol delivered a strong set of results for the year ended 30 June 2021

Retrieved on: 
Monday, August 16, 2021
CFO, EBITDA, Audit committee, SENS, RCF, Company, IAS, SA, Q&A, Retirement, Webcast, Board, Investment, Risk management, New, JSE, Safety, Capital market, PricewaterhouseCoopers, Bank, Animal, Audit, Management, Renewable energy

This will create valuable financial flexibility as we execute our Future Sasol strategy in the midst of an uncertain macroeconomic environment.

Key Points: 
  • This will create valuable financial flexibility as we execute our Future Sasol strategy in the midst of an uncertain macroeconomic environment.
  • Our objective remains to steer the balance sheet metrics toward restoration of our investment grade levels.
  • At 30 June 2021, our total debt was R102,9 billion compared to R189,7 billion at 30 June 2020.
  • Our gearing decreased from 117,0% at 30 June 2020 to 61,5% at 30 June 2021 mainly due to repayment of US dollar debt and a stronger closing rand/US dollar exchange rate.

Senseonics Holdings, Inc. Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, August 9, 2021
Health, Medical Devices, Diabetes, Technology, Mobile, Wireless, Software, Biotechnology, Investment, Eastern Time Zone, MARD, COVID-19, FDA, Trial of the century, Â, CGM, SENS, Safety, PMA, Accuracy and precision, Telephone, Patient, NYSE, Awareness, Conference, ATTD, Manuscript, Marketing, Doctor of Philosophy, Diabetes, Research, Total, Next Generation, Program, ADA, Medical device, Video game, Pharmaceutical industry, Life insurance, Drug

Total revenue for the quarter was $3.29 million compared to $0.26 million for the second quarter of 2020.

Key Points: 
  • Total revenue for the quarter was $3.29 million compared to $0.26 million for the second quarter of 2020.
  • Second quarter 2021 research and development expenses increased by $3.31 million year-over-year, to $7.11 million.
  • Second quarter 2021 general and administrative expenses increased by $3.09 million year-over-year, to $7.53 million.
  • Net loss was $180.32 million, or $0.42 per share, in the second quarter of 2021, compared to $7.52 million, or $0.03 per share, in the second quarter of 2020.